Treatment method for microbial infection

Abstract

A treatment composition for treating or preventing bovine mastitis, the treatment composition characterized in that it includes at least two components which have an isoelectric point of or above substantially 6.8 and is extracted from milk, or a milk derived substance.

Claims

1. A method of treating a microbial infection caused by gram-positive bacteria or gram-negative bacteria in a mammal in need thereof comprising administering a formulation, the formulation including a therapeutically effective amount of a cationic fraction that has been eluted from whole milk, processed milk or whey, wherein the cationic fraction comprises: a. a component selected from the group consisting of cathelicidin-1 and serum amyloid A protein; b. chitinase-like protein (CLP-1); and c. lactoperoxidase, angiogenin, quiescin, jacalin-like protein and lactoferrin all of which are from the cationic fraction; and d. a mixture of cationic peptides all of which are from the cationic fraction, wherein the formulation is adapted to be applied directly onto or into a site of microbial infection.

2. The method of claim 1, wherein the microbial infection is caused by at least one of Streptococcus uberis, Staphylococcus aureus or Escherichia coli.

3. The method as claimed in claim 1 for the treatment of bovine mastitis.

4. The method of claim 1, wherein the method is used for treating mastitis in a cow during a drying off or a dry period.

5. The method of claim 1, wherein the method is used for treating mastitis in a cow during a lactation period.

6. The method of claim 1 wherein the method includes applying the formulation onto or into at least one bovine teat.

7. The method of claim 1, wherein the formulation includes one or more of the following: a. a peroxidase substrate source being sodium thiocyanate, and/or b. a hydrogen peroxide source being ascorbate or ascorbic acid.

8. The method of claim 1, wherein the formulation includes one or more of the following: N-acetyl glucosaminidase, defensin, lysozyme, at least one immunoglobulin or at least one growth factor.

9. The method of claim 1, wherein the formulation includes one or more of the following: antibiotics, analgesics, carriers, buffers, preservatives, excipients, controlled release components, hardening or any other pharmaceutically acceptable component.

10. The method of claim 1, wherein the formulation includes a cell lysing substance.

11. The method of claim 1, wherein the formulation includes a detergent, monoglyceride and/or monolauryl glycerol.

Description

BRIEF DESCRIPTION OF DRAWINGS

(1) Further aspects of the present invention will become apparent from the following description which is given by way of example only and with reference to the accompanying drawings in which:

(2) FIG. 1 shows the general elution profile of all the fractions from cation exchange

(3) FIG. 2 shows the fractions separated on SDS_PAGE, and indicates the band that was excised for Mass Spectroscopy and identified as bovine angiogenin,

(4) FIG. 3 shows a radial diffusion assay plate, for Streptococcus uberis,

(5) FIG. 4 shows a radial diffusion assay plate, for Staphylococcus aureus,

(6) FIG. 5 shows a graph of Escherichia coli inhibition using the cationic fraction alone, and with 40 ppm of sodium thiocyanate,

(7) FIG. 6 shows a graph of Streptococcus uberis inhibition using the cationic fraction alone, and with 75 ppm of sodium thiocyanate and 150 ppm of ascorbate,

(8) FIG. 7 shows a graph of Streptococcus uberis growth using various ub-fractions of the cationic fraction, a recombined cationic fraction and an unfractionated (whole) cationic fraction,

(9) FIG. 8 shows a graph of Escherichia coli growth using various sub-fractions of the cationic fraction, a recombined cationic fraction and an unfractionated (whole) cationic fraction,

(10) FIG. 9 shows a graph of Staphylococcus aureus growth using various sub-fractions of the cationic fraction, a recombined cationic fraction and an unfractionated (whole) cationic fraction,

(11) FIG. 10 shows a graph of the effect of the cationic fraction on the growth of Streptococcus uberis in full cream milk,

(12) FIG. 11 shows a graph of the effect of the cationic fraction on the growth of Escherichia coli in nutrient media in a microtitre plate,

(13) FIG. 12 shows a graph of the effect of the cationic fraction on the growth of Staphylococcus aureus in nutrient media in a microtitre plate.

BEST MODES FOR CARRYING OUT THE INVENTION

(14) FIG. 1 shows the elution profile of the cationic fraction from cation exchange. This represents all the protein peaks (as detected at 280 nm) that would be present in a single fraction eluted in a gradient from 80-100 mS. The main components in the cationic fraction are immunoglogulin, lactoperoxidase, lactoferrin, and a group of minor components that include angiogenin.

(15) FIG. 2 shows the main fractions separated on SDS-PAGE, and indicates the band that was excised for Mass Spectroscopy and identified as bovine angiogenin.

(16) The immunoglobulin fraction shows PIGR (76 kDa) as the predominant band, and the heavy (52 kDa) and light chains of immunoglobulin.

(17) The Lp fraction is mainly lactoperoxidase with a small amounts of heavy and light chains of immunoglobulin and angiogenin.

(18) The intermediate fraction has a prominent band of lactoperoxidase and lactoferrin (80 kDa) and a band at around 15 kDa that was identified by Mass Spectrometry as angiogenin, a band at approximately 13 kDa that was identified by Mass Spectrometry as jacalin-like.

(19) The Lf fraction is predominantly lactoferrin (80 kDa).

(20) Experimentation Undertaken:

(21) To test the hypothesis that the cationic fraction could be used as a successful naturally-derived inhibitory product, a variety of in vitro experiments have been conducted on the inhibitory effect of the cationic fractions captured from milk by cation exchange. These experiments have been summarized into several areas. 1. Radial Diffusion (RD) agar assays 2. Minimum Inhibitory Concentration (MIC) assays in microtitre plates

(22) The applicant has also tested various cationic sub-fractions versus the total cationic fraction to determine inhibition efficacy against the three most common major mastitis-causing pathogens: Streptococcus uberis, Staphylococcus aureus and Escherichia coli.

(23) The applicants have also aimed to form a formulation that is effective against all three pathogens. Since the activity of the fraction was lower against certain pathogens, the applicant has also explored various additives to the formulation to achieve this one formulation goal.

(24) 1. Extraction of the Cation Fraction

(25) The process of producing the cationic fraction involved fractionating milk through a cation exchange resin, eluting the bound components from the resin using a salt solution, which can be either a one-step high molarity (>1M) salt or a gradient elution from a lower molarity up to over 1M, collecting the eluted components in a single fraction, and then desalting and purifying the collected fraction.

(26) The cationic fraction was analysed for its constituent components, and the results shown in Tables 2 and 3 (reproduced below). Table 2 shows a typical result for yield and identity of the major proteins identified in the cationic protein fraction.

(27) This particular cationic fraction was captured from raw, whole milk. Growth factors, TGFB 1, TGFB 2, IGF1 and IGF2 are present in low amounts, and are detectable by ELISA in freeze dried concentrates (Table 3).

(28) TABLE-US-00004 TABLE 2 Sub-fractions from the cationic fraction, as measured by Mass Spectrometry (MS). (.sup.1Lactoperoxidase was determined via extinction coefficient rather than MS.) Total Protein estimated Identity from MS (mg/ml) % of total purity (%) lactoperoxidase.sup.1 4.2 8.0% 95% quiescin 1.6 3.0% 50% jacalin-like protein 1.4 2.7% 60% chitinase-like protein 0.4 0.8% 80% angiogenin 10.0 19.0% 60% lactoferrin 35.0 66.5% 95%

(29) TABLE-US-00005 TABLE 3 Enzyme-linked Immunsorbent Assay (ELISA) measurement of growth factors in the cationic fraction TGFB1 TGFB2 IGF1 IGF2 Fraction (ng/mg) (ng/mg) (ng/mg) (ng/mg) angiogenin fraction 2.0 14.5 2.2 4.7 lactoperoxidase fraction 7.0 109.0 4.0 5.0
2 Radial Diffusion Assay
Methodology Growth medium (appropriate for the selected organism) was inoculated with a fresh culture of the organism and poured in a thin layer into a petri dish. When the agar set, wells were cut (with a sterile cork borer), the agar plug was removed, and each well was filled with a test sample. The petri dishes were incubated overnight (at the temperature appropriate for the organism). If the test sample has inhibited the growth of the organism, clear zones with no growth were observed around the wells.
Results Summary

(30) FIG. 3 shows a radial diffusion assay plate for Streptococcus uberis. In this experiment, the goal was to test various additives into the formulation, isolating the additives' effect from the cationic fraction's effects. On this plate, the sources were (1) whole cationic fraction (20-40 mg/ml) with sodium thiocyanate (500 ppm) and monoglyceride (250 ppm) and (2) sodium thiocyanate (500 ppm) and monoglyceride (250 ppm) alone. The total formulation is shown in four spots starting clockwise from the 12 o'clock position. The additives alone spot is in the o'clock position. Consistently large and clear zones for the total formulation can be seen, while no inhibition from the additives alone was observed.

(31) FIG. 4 shows a radial diffusion assay plate tested against Staphylococcus aureus. In this experiment, various combinations of the cationic fraction with and without the additives, sodium thiocyanate (500 ppm) and monoglyceride (250 ppm), were used. While the inhibitory effects were less than those against Streptococcus uberis, one can see that the cationic fraction alone (3 o'clock position) and the total formulation (6 o'clock position) resulted in inhibitory zones. The additives alone (12 o'clock position) and the cationic fraction with sodium thiocyanate (9 o'clock position) achieved no inhibition, suggesting that the monoglyceride is a key component for the formulation against Staphylococcus aureus.

(32) 3 Minimum Inhibitory Concentration (MIC) Assays

(33) Assays in microtitre plates, while more time consuming, allow a greater range of dilutions of sample and additives to be tested. Also samples can be taken from the wells with no growth to determine whether the organisms have been killed or merely inhibited.

(34) Methodology

(35) Dilutions of the test sample plus various additives were placed in the wells of a microtitre plate. A small inoculum of the bacterial culture was added to each well. The plate was incubated at the appropriate temperature. A spectrophotometric microtitre plate reader was used to measure the turbidity (absorbance at 450 nm) in each of 96 wells every 30 minutes for 18 hours.
Results Summary

(36) In graphical form, FIG. 5 shows the extent of growth of the Escherichia coli indicated by the height of the bars. The shortest bars show maximum inhibition of growth. For this figure, the left-hand bars indicate that some inhibition of growth is achieved with the cationic fraction alone at a concentration of 1 mg/ml. However, adding 40 ppm of sodium thiocyanate to the cationic fraction allowed total growth inhibition to occur at a cationic fraction concentration of 2 mg/ml. This indicates that lactoperoxidase contributes to the antimicrobial activity when its substrate (thiocyanate) is included.

(37) FIG. 6 shows the results of a different formulation of the cationic fraction against Streptococcus uberis, this time using sodium thiocyanate (75 ppm) and ascorbate (150 ppm). Against Streptococcus uberis, there is no inhibition in vitro using the cationic fraction alone up to 0.8 mg/ml. However, adding sodium thiocyanate and ascorbate shows an inhibitory effect occurring as low as 0.2 mg/ml of the cationic fraction. This confirms that in the absence of milk (or another natural source of substrates) the addition of thiocyanate (as substrate) and ascorbate (as a source of peroxide) is essential for inhibition of Streptococcus uberis.

(38) Note that in FIG. 6, none of the additives were totally inhibitory on their own. The samples labeled 0 in the figure are buffer-only and additive-only samples.

(39) In order to determine conclusively that the total cationic fraction is at work in a synergistic way, MIC experiments were set up using Staphylococcus aureus as the pathogens. A target formulation of sodium thiocyanate (20 ppm) and ascorbate (20 ppm) was chosen from past experimental work. The cationic fraction was fractionated by size-exclusion chromatography into six (6) individual sub-fractions, each containing a major bioactive protein constituent of the total cationic fraction. Each of these six (6) individual fractions was then recombined to form a seventh treatment. Finally, an unfractionated cationic fraction was tested as an eighth treatment. Concentrations of each cationic fraction were chosen such that each sub-fraction protein content from Table 2 was adjusted so that it was equivalent to its concentration in the recombined sample.

(40) FIG. 7 shows the growth of Streptococcus uberis after 12 hr for each sample. Note that for this pathogen, the Lp fraction itself shows as much inhibition as the total cationic fraction. FIG. 8 shows the growth of Escherichia coli after 18 hr for each sample. For this pathogen, the total cationic fraction is required to achieve maximum inhibition. This is also the case for Staphylococcus aureus (FIG. 9). The conclusion from these experiments is that, in order to achieve a target formulation active against all three major mastitis pathogens, the total cationic fraction is required. Recombining individual sub-fractions could be used, however, a total eluted fraction would be preferred.

(41) At this stage, there is strong evidence that a total cationic fraction from the milk inhibits the growth of all three of the most common mastitis pathogens to varying degrees. While pathogen-specific formulations could be made, we also believe that a formulation can be achieved that can be commonly used against all three pathogens.

(42) 4. Test of Growth in Full Cream Milk and Nutrient Media

(43) The effect of the cationic fraction on the growth of Streptococcus uberis in full cream milk was tested, with results shown in FIG. 10.

(44) At time zero autoclaved milk was inoculated with 0.1 ml of Streptococcus uberis (1/1000 dilution of logarithmic phase growth in trypticase soy broth). After two hours cationic fraction at a final concentration of 5 mg protein/ml was added to two flasks and two were kept as controls. Samples were removed for plate counts at hourly intervals. The growth curves (average of the plate counts) are shown in FIG. 10. The addition of the cationic fraction has inhibited the growth of Streptococcus uberis while the control has reached maximum growth in 7 hours. This experiment shows that there was no requirement for the addition of thiocyanate or ascorbate when Streptococcus uberis was grown in milk.

(45) The effect of the cationic fraction on the growth of Escherichia coli and Staphylococcus aureus is shown in FIGS. 11 and 12.

(46) 5. Efficacy Trial

(47) The applicant is undertaking efficacy trials in the next six months.

(48) The basis for this trial is as follows: Aims: determine efficiency of treatment, and whether there are any toxicity issues with either the cationic fraction or additives/carries. The carrier used in the trial is likely to be Ringer's saltshowever this may differ from the carrier used in the final commercial formulation. The full cationic fraction and additives are being used for the trial. A repeat milk growth curve experiment is to be used to determine the desired final concentration. The concentrations to be used are as follows (these may be higher than the final formulation): Cationic fraction: 50-84 mg/ml NaSCN: 20-100 ppm Ascorbate: 20-100 ppm Monoglycerol: 5-20 ppm Size of dose is to be 10 ml, and will aim for 3 doses Will focus on Streptococcus uberis sub-clinical mastitis initially, will also possibly look at Staphylococcus aureus. Will initially look at 15 cases of sub clinical Streptococcus uberis mastitis to ensure at least 10 valid treatment subjects. Selection criteriano exclusions will be made on lactation stage, age or breed.

(49) Aspects of the present invention have been described by way of example only and it should be appreciated that modifications and additions may be made thereto without departing from the scope thereof.

REFERENCES

(50) Bramley, A. J., Dodd, F. H. 1984. Reviews on the progress of dairy scienceMastitis Control. J. Dairy. Res. 51: 481-512 Dillehay D. L., Webb S. J., Schmelz E.-M., Merrill A. H. Jr. Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1 mice. J. Nutr., 1994; 124:615-620 Merrill, A. H., Schmelz, E-M., Wang, E., Dillehay, D. L., Rice, L. G., Filmore Meredith, and Riley, R. T. Importance of Sphingolipids and Inhibitors of Sphingolipid Metabolism as Components of Animal Diets. The Journal of Nutrition. 127 (5) May 1997. 830S-833S Isaacs C. E., Litov R. E., Thormar H. 1995. Antimicrobial activity of lipids added to human milk, infant formula, and bovine milk. Journal of Nutritional Biochemistry. 6: 362-366 Kussendrager, K. D. and van Hooijdonk, A. C. M. 2000. Lactoperoxidase: physico-chemical properties, occurrence, mechanism of action and applications. British Journal of Nutrition 84: Suppl. 1, S19-S25 Malinowski, E., Klossowska, A., Kaczmarowski, M., Lassa, H., and Kuzma, K. 2002. Antimicrobial Susceptibility of Staphylococci Isolated from Affected with Mastitis Cows. Bull. Vet. Inst. Pulawy. 46: 289-294 Merrill, A. H., Jr. & Sweeley, C. C. (1996) Sphingolipid metabolism and cell signalling. In: New Comprehensive Biochemistry: Biochemistry of Lipids, Lipoproteins, and Membranes (Vance, D. E. & Vance, J. E., eds.), pp. 309-338. Elsevier Science, Amsterdam, The Netherlands Newburg, D. S., 1996. Oligosaccharides and glycoconjugates in human milk: their role in host defense. J. Mann. Gland Biol. Neoplasia 1, 271-282. Reiter, B and Oran, J. D. 1967. Bacterial inhibitors in milk and other biological fluids. Nature (Lond.) 216: 328-33 Schanbacher, F. L., Smith, K. L. 1975. Formation and role of unusual whey proteins and enzymes: relation to mammary function. J. Dairy Sci. 58: 1048-1062 Smolenski, G., Haines, S., Kwan, F. Y.-S., Bond, J., Farr, V., Davis, S. R., Stelwagen, K. and Wheeler, T. 2007. Characterisation of Host Defence proteins in Milk using a Proteomic approach. J. Proteome Research 6 (1):207-215 Talhouk, R. S., Neiswander, R. L., Scanbacher, F. I. 1996. Developmental regulation and partial characterization of growth factors in the bovine mammary gland. J. Repro. Fert. 106: 221-230